NSL-YHJ-2-27

N/A

Report date: 2026/04/13 20:02:18
NME

Base Information

Drug NameNSL-YHJ-2-27
Drug Alias NameNSL-BA-040NSL-YHJ-2-46NSL-100NSL-BA-055NSL-YHJ-2-44 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog inhibitors
TargetsGTPase KRas
Therapy Area/IndicationsPancreatic NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesFlorida A&M University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFlorida A&M University
Active IndicationsN/A
Inactive IndicationsPancreatic NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A